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BMI = Body mass index 
Cu-IUD = Copper intrauterine device 
EQoL = Euro-Quality of Life questionnaire 
hCG = Human chorionic gonadotropin 
HR = Hazard ratio  
IQR = Interquartile range 
ITT = Intention-to-treat analysis 
IUD = Intrauterine device 
LARC = Long-acting reversible contraception 
LNG-IUS = Levonorgestrel-releasing intrauterine system 
MFSQ = McCoy Female Sexuality Questionnaire 
MTOP = Medical termination of pregnancy 
OC = Oral contraceptives 
PHC = Primary health care 
PP = Per protocol analysis 
QoL = Quality of life 
STAI = State-trait anxiety inventory 
TOP = Termination of pregnancy 
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In Finland more than every third abortion is performed to a woman with 
history of previous abortion, which indicates suboptimal contraceptive use 
and inadequacy of postabortion contraceptive services. Previous studies 
have shown that long-acting reversible contraceptive (LARC) methods, 
especially intrauterine devices (IUD) are most efficient in preventing repeat 
unwanted pregnancy. IUDs can usually be inserted at the time of surgical 
termination of pregnancy (TOP). After medical TOP (MTOP), an IUD can be 
inserted when the abortion is shown to be complete, commonly 1–4 weeks 
afterwards, according to various recommendations. However, attendance at 
post-abortion contraceptive visits is poor, and thus the planned IUD insertion 
often fails. 
We have conducted a randomized trial assessing early postabortal IUD 
insertion provided comprehensively as a part of abortion services. 
Altogether 748 women undergoing a first trimester TOP were recruited and 
randomized into two groups. Women in the intervention group received an 
IUD (either a LNG-IUS or a Cu-IUD, according to the woman’s choice), at the 
hospital providing the TOP, either at the time of surgical TOP or at a follow-
up visit 1–4 weeks after MTOP. Women in the control group were prescribed 
oral contraceptives and advised to contact their primary health care (PHC) 
unit for IUD insertion, according to the current practice and the national 
guideline. All study participants were provided with a questionnaire 
assessing anxiety, quality of life (QoL) and sexual well-being at baseline, as 
well as three months and one year after the TOP. 
The primary outcome was to assess the effects of the intervention on the 
incidence of subsequent TOP, when compared to the normal practice. In this 
thesis, the results of the first year are described. In addition, incidence of 
complications related to early IUD insertion, as well as compliance to post-
abortion care and IUD insertion were assessed in women choosing MTOP. As 
secondary outcomes, mental health and sexual well-being during the first 
year after TOP was assessed. 
During the first year of follow-up after TOP, a significant difference between 
the two study groups was seen in the attendance at follow-up, in receiving 
the planned IUD, and in the incidence of repeat unwanted pregnancy. The 
early insertion of IUD after MTOP was safe and did not increase the risk of 
severe complications or IUD expulsions.  
In the entire study population general reduction of anxiety was seen at three 
month and one year, compared to baseline. Concordantly, a better quality of 
life was generally reported after three months. Regarding overall sexual well-
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being, there was no significant change during the follow-up. Better rates in 
the sexuality questionnaire, i.e. better sexual well-being, were associated 
with having a relationship, and correlated positively with frequency of 
intercourse, quality of life, and negatively with anxiety. Contraceptive 
method appeared to have little effect on overall sexual well-being. However, 
at three months, IUD users had better scores of sexual well-being, compared 
to users of other methods. 
This study shows that providing TOP and IUD insertion comprehensively at 
the same unit with minimal delay results in higher attendance at follow-up, 
higher uptake of IUD and a reduced need of subsequent TOP during one-year 






Fifty years ago, at the United Nations International Conference on Human 
Rights in Tehran on 13 May 1968, it was declared that ‘The parents have a 
basic human right to determine freely and responsibly the number and the 
spacing of their children’.1 Yet, even today more than 200 million women lack 
a contraceptive method in the developing countries.2 In many developed 
countries, a woman’s access to contraception and right to abortion is still 
being questioned or strictly restricted. 
In Finland, the current abortion law dates back to 1970, when abortion based 
on social grounds was legalized. Based on this law, a woman is granted 
permission to abortion in practically all cases with a pregnancy under 20 
weeks of gestation. Yet, unlike in some other western societies, the abortion 
is not granted only by request, but must have an indication, and be granted 
by one or two physicians, or by the National Supervisory Authority for 
Welfare and Health, depending on the gestational weeks and the indication. 
Most often (in 93% of all cases in 2017) the indication for abortion is “social 
distress”, based on the woman’s own notion.3  
Since 1972, the communities have been obliged by the law to provide 
contraceptive counselling visits free of charge for women in all ages.4 
Providing and subsidizing contraceptive methods are decided on a 
communal level, and thus the extent of the cost-free services differ greatly 
across Finland. 
In Finland, approximately 9 500 TOPs are performed every year, and their 
number has been slightly decreasing during the past decade.3 When 
comparing to other European countries, the incidence is relatively low 
(8.2/1000 fertile aged [15–49 years] women). However, during the past 15 
years the proportion of repeat TOP has been increasing despite the rather 
easy availability of public contraceptive services. During 2017, 38% of all 
TOPs were performed in women who had a history of previous TOP, whereas 
in 2000 the figure was 29%. This is likely to reflect an unmet need of 
contraceptive counseling and services and poor adherence to contraceptive 
use in a significant proportion of women.  
Repeat surgical TOPs have been associated with elevated risk for preterm 
delivery and low birth weight in subsequent pregnancies. Although such 
risks are not associated with medical TOP (MTOP), repeat MTOP can increase 
the risk of surgical interventions.5,6  
In several Northern European countries, including Finland, the method of 
induced abortion has changed rapidly since the introduction of medical 
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abortion, i.e. the combination of antiprogestin mifepristone and 
prostaglandin analogue misoprostol, in the early 2000s. In 2017, 97% of all 
induced abortions in Finland were medical, which is the highest rate 
worldwide. In a majority of abortions performed before 9 weeks of gestation, 
misoprostol can be self-administered at home. Despite many positive aspects 
of the broadening of alternatives and the individualization of abortion care, 
the current abortion process produces new challenges for prompt provision 
of effective contraception, especially that of IUDs. As surgical abortion is 
becoming a rarity, new strategies of organizing IUD provision following 
medical abortion need to be developed to promote rapid initiation of 
effective contraception.  
During the past years, long-acting reversible contraception (LARC) methods 
have become the preferable contraceptive choice in all women.7,8 LARCs are 
not user-dependent, and thus do not require a continuous adherence to use. 
Therefore, the chance of contraceptive failure due to imperfect use is 
practically avoided. The efficacy of LARCs, and IUDs in particular, in 
preventing repeat TOP is well established.7-13  
The timing of IUD initiation after medical abortion has been the subject of 
several recent studies. The key question is how to obtain the shortest 
possible delay in IUD insertion without unduly increasing the potential risks 
of expulsion, infection or other adverse events. This is an important issue, 
not only from the ethical principle to avoid causing harm to a patient, but 
also from the perspective of optimizing cost-effective contraceptive service 
provision without the burden of additional visits.  
Attendance at postabortal and LARC initiation visits is likely to depend on the 
service provision system; accessibility of services, flexibility of scheduling 
appointments, costs of the method and the services, and in some cases, 
distance and transportation to the clinic. Attitudes, perceptions and skills of 
the health care professionals also have an impact on how and whom LARCs 
are recommended and provided to. In countries where contraceptive visits 
or methods are not subventioned or provided by the society, socioeconomic 
backgrounds of women affect their choices of contraceptive methods.7,14,15  
However, little is known about factors affecting attendance and compliance 
to LARC provision in a setting where these methods are provided free of 
charge. When the economic barriers are removed, and even logistics are not 
an issue, the factors related to the service provision practices and to the 
background characteristics of the individual become more relevant. 
Induced abortion and its possible psychological implications are a matter of 
disputation. Information and even research regarding this issue are often 
Terminology  
a state of physical, emotional, mental and social 
well-being in relation to sexuality; it is not merely the absence of disease, 
dysfunction or infirmity. Sexual health requires a positive and respectful 
approach to sexuality and sexual relationships, as well as the possibility of 
having pleasurable and safe sexual experiences, free of coercion, discrimination 
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and violence. For sexual health to be attained and maintained, the sexual rights 




4 Review of the literature 




Figure 1. Incidence of induced abortion /1000 fertile-aged women. Sources: WHO, Guttmacher Institute, UN: World Abortion 




Figure 2. Legality of abortion worldwide in 2018. Sources: WHO, Guttmacher Institute, Center for Reproductive Rights, 
www.worldabortionlaws.com. Created with mapchart.net.  
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When looking at the recent Finnish National abortion statistics, a declining 
trend can be seen in the overall abortion rate, as well as in abortions in the 
age groups of teenagers and 20–24 years, the latter still presenting the 
highest abortion rates (Figure 3). On the contrary, an opposite, upward trend 
can be seen in the abortion rates of women aged 25–39, and in a longer term, 
in repeat abortions.3  
During the past years, contraceptive services of adolescent and young 
women have been visibly discussed in public, and some municipalities have 
expanded provision of cost-free contraception in these age groups. This 
might be one of the reasons behind the declining trends in teenage abortions 
seen in the national abortion statistics. However, a continuous increase in the 
rate of repeat abortions clearly indicates that there is a large proportion of 
women with an unmet need for postabortal counselling and contraception. 
 
 
Figure 3. Abortion rate (/1000 women of corresponding age) in Finland 
according to age groups. (Data derived from: www.thl.fi) 
 
4.1.1 Finnish legislation and policies 
According to the Finnish legislation, induced abortion can be performed at 
permission by one physician before the 13th week of gestation if the woman 
is aged under 17 or more than 40 years at the time of conception or has given 
birth to four or more children. Up to 12+0 weeks of gestation, a permission 
by two physicians is needed for other reasons, such as social indications, risk 
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for the mother’s health caused by pregnancy or delivery, or if the pregnancy 
is the result of rape or another sexual crime. For abortions performed at 12–
20 gestational weeks, and for all abortions performed due to fetal 
indications, a permission from the National Supervisory Authority for 
Welfare and Health is required. In cases of severe fetal anomaly, a pregnancy 
can be terminated at up to 24 weeks.31 The principles of the Finnish abortion 
legislation are presented in Table 1. A pregnancy can be terminated by 
decision of two physicians regardless of the duration of pregnancy if 
continuing the pregnancy or giving birth to the child would seriously 
endanger the woman’s life or health. 
 
Table 1. Abortion legislation in Finland 
Duration of 
pregnancy 
Age <17 or >40,  





≤ 12 weeks 1 physician 2 physicians 2 physicians 
12+1 – 20 weeks Valvira1 Valvira Valvira 
20+1 – 24 weeks - - Valvira 
 
1National Supervisory Authority for Wefare and Health 
2Giving birth to the child and the child's care would impose considerable strain on the woman. 
 
In Finland, 93% of all abortions are performed due to social indications in, 
and 92% take place before 12 weeks of gestation.3 Approximately 99% of 
TOPs are performed in public hospitals (Anna Heino, personal 
communication 9.11.2018), to which women can be referred by physicians 
from the PHC or private clinics. In at least 67% of MTOP performed before 9 
weeks of gestation, misoprostol is self-administered at home. (Anna Heino, 
personal communication 16.11.2018) After TOP, follow-up and contraceptive 
services after abortion are meant to take place in the referring PHC unit, 
allowing contraceptive counselling and planning at the time of referral. 
However, women can choose to use private clinics at own expense for 
contraceptive services. Some private clinics provide abortion care, for which 
they must have obtained a registered permission from the National 
Supervisory Authority for Welfare and Health.  
The Finnish National guideline on induced abortion was first introduced in 
2001, and last updated in 2013.32 The method of a first trimester TOP is 
decided individually according to the woman’s choice. In 2017, 97% of all 
TOPs were performed by using the medical method.3 All induced abortions 
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are reported to the National abortion registry kept by the National Institute 
for Health and Welfare. The reporting is mandatory by the law.33  
 
Figure 4. Method of induced abortion in Finland. (Data derived from: Abortion 
statistics, National Institute for Health and Welfare 2018) 
 
4.1.2 Medical and surgical abortion 
In the 1970’s, natural prostaglandins were found to induce abortion, but 
caused intolerable gastrointestinal side-effects. In the early 1980’s 
prostaglandin analogues, such as gemeprost and sulprostone, which were 
more selective to the myometrium were developed.34,35  
The antiprogestin mifepristone (RU-486) was developed in the early 1980’s 
and applied in clinical testing in 1982, in which the rate of ongoing 
pregnancy was found to be around 60–80% with monotherapy.36-38 In the 
mid-80’s it was found that combining a prostaglandin analogue to the 
treatment resulted in an efficacy close to 100% with considerably fewer side-
effects.38 The medical method of induced abortion by combination of 
mifepristone and a prostaglandin analogue was legalized in France and China 
in 1988, followed by Great Britain in 1991 and Sweden in 1992.39  
Since the introduction of medical abortion with mifepristone in Finland and 
several other European countries in 2000, its use has rapidly increased. For 
the past 15 years it has become the most frequently used method in Finland 
as well as in many other European countries.3,40-42 
Return of ovarian function and fertility after 
abortion 
 
Contraceptive methods; efficacy, adherence 
continuation 
4.3.1 in primary prevention 
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Table 2. Efficacy and continuation of contraceptive methods according to 
various sources. 
A* Summarized from clinical studies: Mansour et al 2010,52 Lakha 2006,53 O’Neil 2013,54 
Peipert 201155. Pearl index indicates the number of pregnancies per 100 women during 1-
year use of the method. 
B** WHO MEC 2015, source: Trussell J. Contraceptive efficacy. In: Hatcher RA, Trussell J, 
Nelson AL, Cates W, Kowal D, Policar M, editors. Contraceptive technology: twentieth revised 
edition. New York (NY): Ardent Media; 2011. 
 
The 1-year continuation rates of LARC methods are notably higher than that 
of non-LARCS. In LARC users, the most common reasons for discontinuing 
use of the implant are frequent or unpredictable bleedings,53,56 whereas IUD 
removals are most often performed due to inconvenient bleeding patterns or 
pain,57 and this occurs most commonly during the first 6 months of use.58 
After initiation of LNG-IUS use, irregular bleeding and spotting are common 
during the first 3–4 months.59 Due to progressive reduction of menstrual 
bleeding, amenorrhea is achieved in 44% of users at 6 months, and in 50% at 
one year.58  
Intrauterine contraception is one of the most effective reversible methods of 
contraception with Pearl index of 0.1–0.2 regarding LNG-IUS and 0.6–0.8 Cu-







nuation rate (%) 
Method A* B** A* B** A* B** 
OC 0.0–1.3 0.3 0.0–2.2 9 55–59 67 
Ring 0.3–1.0 0.3 0.3–1.2 9 56 67 
Patch 0.6–1.0 0.3 0.7–1.2 9 50 67 
Implant 0.1 0.1 0.1 0.1 74–87 84 
Cu-IUD 0.6 0.6 0.8 0.8 84–93 78 
LNG-IUS 0.1–0.2 0.2 0.1–0.2 0.2 88–93 80 
       
LARC methods    82–87  
       
Non-LARC methods    49–59  
       
Male condom 2  18  43 
Withdrawal  4  22  46 
Fertility awareness 
based methods 
0.4–5  24  47 
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compared to short acting reversible methods, because the typical problems 
of imperfect use and user-dependent failure are avoided. Typically, the 
continuation rates at one year are around 88% with LNG-IUS and 84% with 
Cu-IUDs, compared to that of OCs around 55%.55 
Worldwide, the most popular method of contraception is female sterilization, 
whereas IUDs are used by 14.3% of fertile aged, married or in union 
women.60 IUDs are the second most prevalent contraceptive method in the 
developing countries. In Europe the usage rate is 12%, with a wide range of 
variation between countries. In Finland the estimated IUD usage rate is 23%, 
which is the highest in Europe, whereas in the Netherlands, the usage is only 
4%.61 In the USA, the usage rate is as low as 7% but increasing rapidly.60-62  
The overall IUD expulsion rate typically varies around 2–10%.63,64 
Young/adolescent age (14–19 years), parity and a history of previous IUD 
expulsions have been associated with a higher risk of expulsion.65,66 In some 
studies the LNG-IUS has shown lower rates of expulsion compared to copper-
IUDs.63,65 
 
4.3.2 In secondary prevention 
Women undergoing an induced abortion are highly fertile. Based on previous 
studies, the risk of having a subsequent TOP is approximately 15% in five 
years.9 In Finland the proportion of repeat abortions has been increasing 
during the past 15 years, despite the declining trend of the overall number of 
abortions. In 2017 38% of women requesting abortion had a history of one 
or more previous abortions, and 16% had a previous pregnancy ending in 
TOP during the past 5 years.3 This implicates suboptimal provision and use 
of effective contraceptive methods following abortion. 
In previous studies, several risk factors for the need of repeat TOP have been 
identified. These include previous abortion, and especially second trimester 
abortion, smoking, young age and parity.9,67 Previous cohort studies have 
shown that the choice of contraceptive method predicts the risk of repeat 




Figure 5. Proportion of repeat abortions in FInland 2000 - 2016. Source: THL 
Abortion statistics 2000 – 2017 (www.thl.fi). 
Initiation of contraception after termination of 
pregnancy 
Barriers in post-abortion care 





Table 3. Rates of adverse events following surgical or medical TOP. 
 Bjørge108  Knudsen109  Suhonen113  Ashok110  Niinimäki114  White115  
 Medical Medical Medical Medical Medical Surgical Surgical 
Infection  - - - - 1.7 1.7 0–11.6 
Infection requiring surgical evacuation 0.5 2.0% - - 0.8 0.6 - 
Infection requiring intravenous antibiotics - - -  - - 0–7.7 
Hemorrhage - - - - 15.6 2.1 0–4.7 
Bleeding requiring evacuation 0.0 4.0% 1.0 0.2 2.9 0.9 - 
Bleeding requiring blood transfusion - 0 - - - - <0.1 
Residual tissue - - 2.6 - - - - 
Incomplete abortion - - - 2.3 6.7 1.6 - 
Incomplete abortion requiring reabrasion 4.1 - 5.0 1.6 5.9 0.4 <0.1–8.0 




4.6.1 Mental well-being  
The possible effects of abortion on a woman’s mental health are often 
disputed, and sometimes a matter of argumentation colored by stigmatizing 
opinions. Mental health after abortion is difficult to assess reliably, and 
designing a reasonable study is challenging, as reliable data on mental health 
prior to the unwanted pregnancy is usually not available. Latest research on 
the matter shows mainly a neutral effect.116-119 In addition, some evidence 
implies that possible changes in mental health following abortion are related 
to the distress caused by an unwanted pregnancy rather than the abortion 
itself. Furthermore, social and mental problems are likely to be 
overrepresented in women deciding to end the unwanted pregnancy.120-122  
4.6.2 Sexual well-being 
Only few studies have assessed sexual life and well-being after abortion. This 
subject is difficult to examine reliably, because neither subjective nor 
objective data on sexual well-being before the unwanted pregnancy is hardly 
ever accessible. In addition, sexuality, and to an even greater extent, abortion 
are matters of cultural differences, norms and taboos, due to which all 
studies must be seen in the context of the cultural backgrounds they relate 
to. However, in most studies performed in developed countries, the majority 
of women report no effect on sexuality.123-125 Some studies have suggested a 
short-term negative effect in a minority (10–20%) of participants in terms of 
decreased sexual interest or problems in sexual functioning.47,124,126-128   
Previous studies assessing the effects of IUD on sexuality have shown that 
intrauterine contraception has little or no effect on sexual well-being and 





5 Aims of the study 
 
- To evaluate the safety of early IUD insertion after MTOP. (I) 
 
- To assess the success of planned early IUD insertion following MTOP, 
and factors affecting it. (I) 
 
- To compare the effectiveness of two different ways of providing 
contraceptive services, and to assess factors affecting rates of 
attendance at follow-up and IUD usage in women randomized to 
different service tracks. (II) 
 
- To assess the efficacy of routine provision of intrauterine 
contraception after first trimester abortion in reducing the need for 
subsequent abortion. (III) 
 
- To assess anxiety and quality of life after induced abortion, and 
factors affecting it. (IV) 
 
- To assess sexual well-being after induced abortion, and factors 
affecting it. (V) 
  




Table 4. Baseline characteristics of the study participants. The data are 
presented as n (%) unless stated otherwise. 
 Intervention 
Group n = 375 (%) 
Control Group 
n = 373 (%) 
Age (years); median (IQR) 27 (22 to 33) 27 (23 to 33) 
Days of amenorrhea; median (IQR) 57 (49 to 66) 56 (49 to 65) 
Daily smoking 188 (50.1) 189 (51.4) 
Regular use of alcohol 275 (73.3) 286 (77.9) 
History of drug abuse 7 (1.9) 13 (3.5) 
BMI (kg/m2); median (IQR) 23 (21 to 26) 23 (21 to 26) 
History of pregnancy 261 (69.6) 247 (67.3) 
History of delivery 187 (49.9) 175 (46.9) 
History of induced abortion 174 (46.4) 153 (41.0) 
   
Type of induced abortion  
Medical 307 (81.9) 299 (80.2) 
Surgical 68 (18.1) 74 (19.8) 
   
Type of planned contraception  
Cu-IUD 26 (6.9) 24 (6.4) 
LNG-IUS 349 (93.1) 349 (93.6) 
   
Marital status   
Married 71 (18.9) 52 (13.9) 
Cohabiting 102 (27.2) 92 (24.7) 
Single 202 (53.9) 229 (61.4) 
   
Contraception used at the time of conception  
Combined hormonal contraceptives 45 (12.0) 49 (13.1) 
Progestin-only pill 12 (3.2) 9 (2.4) 
Cu-IUD - 1 (0.3) 
Condom  159 (42.4) 135 (36.2) 
Other 8 (2.1) 14 (3.8) 





6.1.1 Interventions and follow-up 
Altogether 748 women were randomized into two groups; 375 in the 
intervention and 373 in the control group. The randomization was 
performed by using the permuted block method. The group assignments 
were kept in sealed envelopes, which the study nurse opened after 
recruitment. The investigators did not take part in the randomization 
process.  
Women in the intervention group received an IUD at the hospital providing 
the abortion either during surgical TOP or at a follow-up visit 1–4 weeks 
after medical TOP. Women choosing a surgical TOP had a follow-up visit 1–4 
weeks after the TOP to ensure correct placement of the IUD, or to have an 
IUD inserted if not placed during the procedure. The type of the IUD (either 
the 52mg levonorgestrel-releasing intrauterine system, LNG-IUS, Mirena® or 
a copper-IUD, Nova-T®, both manufactured by Bayer Ag [Turku, Finland] 
was chosen according to the woman’s preference. Three months after the 
TOP, all women in the intervention group had an appointment with the study 
nurse to assess recovery and to ensure proper placement of the IUD by 
visualizing the IUD strings. Ultrasonography was performed by a study 
physician if the strings appeared missing or too long. In cases of expulsion, a 
new device was inserted. 
Women in the control group were prescribed oral contraceptives and 
advised to contact the PHC for further follow-up and IUD insertion, according 
to current normal practice. The City of Helsinki provided the IUD free of 
charge if the woman had not used intrauterine contraception previously, 
thus the planned IUD was cost free for the majority of women in the control 
group. 
All women were advised to contact the study hospital in cases of suspected 
or diagnosed complications related to TOP. Women in the intervention group 
were advised to contact the study personnel in case of any IUD related 
problems. 
One year after the index TOP, all women were invited to a follow-up visit 
performed by a gynecologist at the Centralized Family Planning Clinic of the 
City of Helsinki. Figure 6 shows the one-year follow-up flow chart. In 
addition, all participants were followed-up for one year via the hospital 
databases, and data on the subsequent TOP’s were obtained from City of 
Helsinki databases and the Abortion registry of the National Institute for 





Figure 6. Flow chart: 1-year follow up and timing of questionnaires. 
 
6.1.2 Questionnaires 
All participants were asked to fill in a questionnaire at the time of the 
recruitment, as well as at three months and one year after the TOP. The 
questionnaire forms consisted of validated inquiries regarding anxiety 
(STAI), quality of life (EQoL) and sexual well-being (MFSQ) as well as 
additional questions regarding health, smoking, alcohol consumption, 
medication, contraception, new pregnancies, relationship status and working 
status.  
The State-Trait Anxiety Index (STAI) is widely used in evaluating the level of 
anxiety. It consists of 40 items in total, half of which composing the state 
subscale measuring current anxiety, and the other half composing the trait 
subscale measuring proneness to anxiety in general. In this study, the state 
scale of the STAI was used to assess the level of anxiety at three time points, 
and to evaluate changes in it during the follow-up time. The state subscale 
consists of 20 items rated on a 4-point Likert scale, higher score indicating 
greater level of anxiety. A cut point of 40 was used as indicative of clinically 
relevant anxiety.132  
Study on the success of early IUD insertion after 
medical termination of pregnancy (I) 
Study on non-compliance (II) 
Study on subsequent termination of pregnancy (III) 
Study on mental health and quality of life (IV) 
Study on sexual well-being (V) 





by using the Mann-Whitney U-test for skewed data (Studies III and V). 
Survival analysis were performed by using Kaplan-Meier analysis (Studies II 
and III). Logistic regression was used to calculate odds ratios (OR) with a 
95% confidence interval (95%CI) (Studies I, II). In assessing correlations of 
continuous variables, Spearman correlation factors were calculated (Study 
V). In study IV, a comprehensive analysis of missingness at random was 



















control group, 38 (12.7%) women had an intervention due to TOP-related 
cause, most of which (60.5%, n=23) took place within the first two weeks 
following abortion. In the intervention group, altogether 82 (26.7%) women 
had an intervention due to TOP-related cause, only 20 (24.4%) of which 
within two weeks’ time interval after TOP (Figure 7). 
 
 
Figure 7. Number of women with a suspected or diagnosed condition or 
adverse event judged to require intervention (medical or surgical treatment of 
residual tissue, antibiotics, blood transfusion) according to time interval from 
TOP to intervention. 
 
 












Figure 8. Compliance to follow-up and IUD insertion among participants 
choosing MTOP (ITT-basis). 
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The cumulative proportion of women without subsequent TOP at one year 
was 98.4% in the intervention group and 95.4% in the control group 
(p=0.019) (Figure 9). The intervention reduced the number requested TOP 
by more than half, and the rate of repeat TOP by almost two thirds. 
 
Figure 9. Survival curve of the study subjects showing proportion of women 
without subsequent unwanted pregnancy during one-year follow-up.  
Group 1= intervention group, Group 2= control group. 

















the rest of the study population. However, the difference was not seen at one 
year. Women using hormonal contraception reported lower rates in the 
dimension of arousal and orgasms at one year, compared to women with 
non-hormonal methods or no contraceptive use (median 10.0 [IQR 5.0], 








Figure 10. McCoy index at three timepoints according to relationship status. 
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A follow-up at 2–4 weeks after TOP, to be performed by a nurse if there are 
no suspected complications, is recommended in the national guidelines on 
TOP. Further, an IUD can be inserted in the PHC at a follow up visit or at the 
time of first menstrual period.32 In practice, the recommended follow up 
comprises often a serum-hCG sample and a telephone contact or an in-
person visit with a nurse, and thus a later appointment with a physician is 
needed for IUD insertion. This practice often produces a delay, which is likely 
to increase the rate of non-attendance. In most PHC units, IUD insertions are 
performed by only few physicians, which can result in difficulty of scheduling 
appointments for IUD insertions. 
In previous studies with a TOP to insertion delay of approximately 3 to 6 
weeks, the rates of receiving the planned IUD has ranged from 19% to 
86%.74,77,83,85 In our study, 75% of the planned IUD insertions in the 
intervention group took place within four weeks after MTOP, as planned, and 
all women who attended follow-up and were willing to have an IUD received 
it by three months. Thus, IUD initiation occurred in 91% of the women in this 
group.  
Of the entire control group, only one in four women received an IUD within 
three months. Further, only less than 40% of the women in the control group 
who had a contact to the PHC received an IUD within 3 months after TOP. 
Thus, non-attendance in this group was likely affected by difficulty in 
scheduling despite attempting to book an appointment. However, altogether 
22% of the women in the control group never contacted the PHC for follow-
up. This reflects a low adherence to post-abortion care and contraceptive 
services when it depends on one’s own initiative and when the unit providing 
the abortion is different than the one providing the post-abortion care. It is of 
notice that in real life, the compliance is likely to be even lower, compared to 
the study setting with highly motivated women. 
In light of these findings it may be suggested that providing abortion and 
contraceptive services comprehensively in the same health care unit, a better 
rate of attendance and IUD usage could be achieved, and the risk of 
subsequent unwanted pregnancy reduced. It might also be useful to have a 
contact person at the health care unit to achieve lower threshold of 
contacting. One of the key findings in our study was the effectiveness of the 
centralized early IUD provision compared to the current practice of IUD 
provision in the PHC, in reducing the need of subsequent TOP.  
In this study, the unit providing the services was a university hospital. 
However, it can be questioned whether it might be reasonable to arrange the 
MTOP and IUD services at PHC. Shifting or sharing tasks between heath care 
Recovery after termination of pregnancy 
Strengths and weaknesses of the study 
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8.7.1 Study I 
This substudy was performed by analyzing adverse events among women 
participating the primary contraceptive trial, according to which the power 
calculations were made. Thus, the population was not sufficient for 
evaluating the incidence of rare events, such as uterine perforation. This can 
be seen as a shortcoming of this secondary analysis. In addition, at the time 
of analyzing the results of this substudy, data of all PHC visits due to TOP-
related indications and early IUD insertions were not available. However, all 
participants were advised to contact the hospital in case of suspected 
complications, and thus any adverse event requiring a hospital visit could be 
detected from the hospital databases.  
There was no significant difference in the incidence of infections requiring 
intravenous treatment between the randomization groups. However, oral 
antibiotics were prescribed more often in the intervention group, half of 
them at the study follow-up visit, based on clinical evaluation at the time of 
IUD insertion.  In the control group, oral antibiotics might have been 
prescribed from the PHC for women with mild symptoms that did not 
require referral to the hospital, and thus, this data was not available in the 
analysis of this study. The difference in oral antibiotic administration 
between the two groups can partially be explained by the experimental 
nature of the study intervention and the effort of being on the safe side in 
avoiding the possible risk of uterine infection in case of suspected mild 
bacterial infection during IUD insertion. Some of these treatments might not 
have been described at all if the IUD insertion had taken place at a later 
timepoint. 
8.7.2 Study II 
This substudy might be criticized for the different follow-up procedures in 
the two groups. However, one of the aims of the study design was to compare 
the current service provision to a more comprehensive one. Indeed, a 
significant difference was seen in the rates of attendance and IUD use 
between the two groups, although all women were voluntary participants in 
a clinical study and interested in IUD contraception. 
8.7.3 Study III 
This study was initially planned for a five-year follow-up. Thus, the power 
calculations were performed based on the assumed incidence of subsequent 
TOP during five years. However, a significant difference in the request for 
subsequent TOP was seen already after the first year of follow-up.  
The number of protocol violations in this study was quite high, especially 
regarding IUD insertions during surgical abortion in the control group. 
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However, the difference between the groups remained significant in the per 
protocol-analysis. 
8.7.4 Study IV and V 
In both of these studies the outcome was measured by validated 
questionnaires, which is a strength. Typically for this group of women and a 
sensitive topic, the adherence and thus also the response rate were rather 
low. Following analysis of the missing data, the missingness was found to be 
a random event in relation to the background factors, and thus the available 
data could be used. 
We were able to assess changes in sexual well-being and mental health 
during the abortion process, and one year onwards. In addition, we could 
analyze how different background factors relate to the women’s well-being 
after abortion. However, to reliably assess the effect of abortion, a reference 
group with no unplanned pregnancies or abortions would have ideally been 
needed. Still, it would be difficult to differentiate the effect of the unplanned 
pregnancy from the effect of abortion. As seen in light of some previous 
studies, designing a study for comparing women undergoing an abortion 
with another group of women is problematic; a group of non-pregnant 
women would lack the possible effects of an early pregnancy, a group of 
women with a planned pregnancy would likely have different backgrounds 
and situation of life (and relationship status). Even without any reference 
group, a baseline questionnaire before the unwanted pregnancy would be 







The following conclusions can be drawn: 
- Early initiation of intrauterine contraception following medical TOP 
is safe and does not increase the risk of IUD expulsion or severe 
complications. (I) 
 
- Providing IUD insertion as an integral part of TOP services leads to 
higher rate of attendance, IUD usage, and significantly decreases the 
incidence of subsequent unwanted pregnancy during the first year. 
(II, III) 
 
- Non-attendance at post-abortion follow-up is associated with history 
of previous deliveries and history of TOP. (II) 
 
- Predictive factors for low compliance in post-abortion care are few, 
and thus providing an option for IUD insertion as an integral part of 
abortion care is justified for all women. (II) 
 
- Recovery after TOP is an individual process and is influenced by 
various background factors. In most women, mental health and 
quality of life are normalized rapidly, and not severely affected in the 
long term. Women with history of psychiatric morbidity, or high 
levels of anxiety at the time of TOP present a minority that might be 
more prone to adverse mental long-term effects. (IV) 
 
- Sexual well-being is multifactorial and associated with mental health, 
good quality of life and being in a relationship, but not significantly 
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